Adeno-Associated Virus (AVV) Vectors In Gene Therapy Global Market Report 2025

The adeno-associated virus (AVV) vectors in gene therapy market size has grown rapidly in recent years. It will grow from $2.7 billion in 2024 to $3.18 billion in 2025 at a compound annual growth rate (CAGR) of 17.7%. The growth during the historic period can be credited to greater investment in gene therapy research, the growing use of gene editing technologies, an increase in genetic disorders and unmet medical needs, rising demand for targeted treatments, and enhanced collaboration between biotechnology companies and research organizations.

The adeno-associated virus (AVV) vectors in gene therapy market size is expected to see rapid growth in the next few years. It will grow to $6.09 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The anticipated growth in the forecast period can be attributed to ongoing advancements in AAV capsid engineering, a heightened emphasis on precision medicine, increasing investments in genetic research and biotechnology, a surge in gene therapy clinical trials and regulatory approvals, and a growing demand for personalized treatment approaches. Key trends expected during this period include the integration of artificial intelligence in AAV capsid design, the development of hybrid AAV vectors capable of carrying larger genetic payloads, innovations in bispecific antibody-mediated AAV targeting, progress in scalable AAV manufacturing and purification methods, and the creation of adaptable AAV platforms that support a variety of viral vector applications.

The rising emphasis on gene-based therapies is expected to drive the growth of the adeno-associated virus (AAV) vectors in the gene therapy market. Gene-based therapies involve the modification or manipulation of genes to prevent, treat, or cure diseases at the molecular level. Advances in genetic research are fueling the development of these therapies by improving the precision and effectiveness of gene editing techniques. AAV vectors play a key role in gene therapy by safely and efficiently delivering therapeutic genes into target cells, thanks to their low immunogenicity and capacity for long-term gene expression. For example, in 2023, IQVIA, a U.S.-based provider of analytics and technology solutions for the life sciences industry, reported that global spending on cell and gene therapies reached $5.9 billion, a 38% increase compared to 2022. As a result, the growing focus on gene-based therapies is contributing to the expansion of the AAV vectors market.

Companies involved in the AAV vectors segment of the gene therapy market are concentrating on technological innovation, such as introducing tailored vector diversity for assay versatility. This strategy enhances tissue specificity, therapeutic effectiveness, and supports the development of customized gene therapies for a range of conditions. Tailored vector diversity refers to the use of various AAV serotypes or constructs to support different analytical procedures and therapeutic applications. For instance, in May 2024, Charles River Laboratories, a U.S.-based pharmaceutical company, launched new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are designed to meet the growing demands of cell and gene therapy (CGT) development, facilitating the transition from early research to GMP-grade manufacturing. The launch aims to standardize production processes and improve consistency in viral vector manufacturing, addressing a major challenge in advancing CGT programs toward clinical and commercial stages.

In March 2023, Ginkgo Bioworks, a U.S.-based biotechnology company, acquired assets related to StrideBio's AAV capsid discovery and engineering platform for an undisclosed amount. This acquisition is intended to strengthen Ginkgo Bioworks’ research and development capabilities in gene therapy, with a focus on creating novel adeno-associated virus (AAV) capsids to enhance gene delivery. StrideBio is a U.S.-based biotech company specializing in the development of engineered AAV capsids for use in gene therapy applications.

Major players in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in adeno-associated virus (AAV) vectors in gene therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adeno-associated virus (AAV) vectors in gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adeno-associated virus (AAV) vectors are advanced gene therapy delivery systems designed to transport genetic material into cells for the treatment of various genetic conditions. Their main objective is to provide targeted and long-lasting therapeutic outcomes by repairing or modifying defective genes. AAV vectors are highly regarded for their safety profile, minimal immune response, and ability to deliver genes to both dividing and non-dividing cells, thereby supporting the creation of precise and lasting gene therapies that enhance personalized medicine and revolutionize the management of rare and inherited diseases.

The primary categories of adeno-associated virus (AAV) vectors include gene augmentation, immunotherapy, and other therapeutic approaches. Gene augmentation involves introducing a functional gene into a cell to replace or supplement a missing or defective one. This can be achieved through various delivery techniques, such as ex vivo and in vivo methods. These therapies are developed and applied at multiple operational stages, including preclinical, clinical, and commercial levels. The targeted therapeutic areas encompass genetic disorders, blood-related diseases, infectious illnesses, metabolic conditions, eye disorders, muscular diseases, and neurological disorders.

The adeno-associated virus (AVV) vectors in gene therapy market research report is one of a series of new reports that provides adeno-associated virus (AVV) vectors in gene therapy market statistics, including precision weight industry global market size, regional shares, competitors with an adeno-associated virus (AVV) vectors in gene therapy market share, precision weight market segments, market trends, and opportunities, and any further data you may need to thrive in the adeno-associated virus (AVV) vectors in gene therapy industry. This adeno-associated virus (AVV) vectors in gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adeno-associated virus (AAV) vectors in gene therapy market consists of revenues earned by entities by providing services such as gene delivery solutions, targeted therapeutic development, long-term gene expression, and treatment of genetic disorders through safe and efficient viral vector technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. The adeno-associated virus (AAV) vectors in gene therapy market includes sales of viral vector delivery systems used for transporting genetic material into patient cells. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.